Despite selling drugs required by patients such as Humira, AbbVie (ABBV) shareholders saw the stock price collapse over 30% similar to the market. In the process, the dividend yield jumped back to an incredibly strong 6.3%. The upcoming closure of the Allergan (AGN) acquisition will provide a further catalyst for the stock that recently traded over $20 higher making the investment thesis as bullish as ever.
Source: Allergan website
Accretive Deal
Both AbbVie and Allergan recently agreed to a consent decree agreement with the FTC. The companies will divest brazikumab and